← Back to Search
Incorporation Of Biomarker Assessment In Novel Clinical Trial Designs: Personalizing Brain Tumor Treatments
E. Galanis, W. Wu, J. Sarkaria, S. Chang, H. Colman, D. Sargent, D. A. Reardon
Published 2011 · Medicine
Download PDFAnalyze on Scholarcy
Advances in molecular genetics have aided the identification of potential biomarkers with significant clinical promise in neurooncology. These advances and the evolution of targeted therapeutics necessitate the development and incorporation of innovative clinical trial designs that can effectively validate and assess the clinical utility of biomarkers. In this article, we review the use and potential of several such designs in neurooncology trials in order to support the development of personalized treatment approaches for brain tumor patients.
This paper references
A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer
I. Cree (2007)
Prognostic Value of 1p, 19q, 9p, 10q, and EGFR‐FISH Analyses in Recurrent Oligodendrogliomas
K. Fallon (2004)
Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma.
A. Brandes (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
R. Stupp (2005)
Oligodendroglial Tumors: Refinement of Candidate Regions on Chromosome Arm 1p and Correlation of 1p/19q Status with Survival
J. Felsberg (2004)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
R. Stupp (2009)
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
W. Wick (2009)
Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
J. S. Smith (2000)
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
D. Hayes (1996)
Bayesian clinical trials
D. Berry (2006)
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors
Maria Möllemann (2005)
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
M. J. van den Bent (2009)
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
R. Verhaak (2010)
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
M. J. van den Bent (2009)
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.
R. Jenkins (2006)
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
M. J. van den Bent (2006)
Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?
D. Hayes (2004)
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
G. Cairncross (2006)
A multigene predictor of outcome in glioblastoma.
H. Colman (2010)
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features
M. J. van den Bent (2003)
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.
H. Phillips (2006)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
I. Mellinghoff (2005)
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
M. Sanson (2009)
MGMT gene silencing and benefit from temozolomide in glioblastoma.
M. Hegi (2005)
Statistical aspects of prognostic factor studies in oncology.
R. Simon (1994)
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines
M. Clarke (2009)
Clinical trial designs for predictive marker validation in cancer treatment trials.
D. Sargent (2005)
Issues and barriers to development of clinically useful tumor markers: a development pathway proposal.
M. Hammond (2002)
This paper is referenced by
IQGAP1 in Podosomes/Invadosomes Is Involved in the Progression of Glioblastoma Multiforme Depending on the Tumor Status
Deborah Rotoli (2017)
A Model for Accelerating Identification and Regulatory Approval of Effective Investigational Agents
J. Woodcock (2012)
The future of glioma treatment: stem cells, nanotechnology and personalized medicine.
M. Rahman (2012)
Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions
M. Bienkowski (2015)
Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on thrombosis in pediatric cardiology and congenital heart disease.
B. W. McCrindle (2014)
Frontiers in Suicide Gene Therapy of Cancer.
M. Malecki (2012)
Phase 2 trial design in neuro-oncology revisited: a report from the RANO group.
E. Galanis (2012)
Next-Generation Sequencing for Cancer Biomarker Discovery
A. Desai (2015)
Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
Miranta Antoniou (2017)
Clinical Application of Molecular Features in Therapeutic Selection and Drug Development
R. Lu (2019)
Thrombosis in Pediatric Cardiology and Congenital Heart Disease Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on Challenges and Priorities for Research: A Report From the National Heart, Lung, and
Ron Portman (2014)
Prognostic and Predictive Biomarkers in Adult and Pediatric Gliomas: Toward Personalized Treatment
H. Haynes (2014)
Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2.
B. Alexander (2013)
A MODEL FOR ACCELERATING IDENTIFICATION AND REGULATORY APPROVAL OF EFFECTIVE INVESTIGATIONAL AGENTS
L. Esserman (2012)
Simulating Gene Expression Data To Estimate Sample Size For Class and Biomarker Discovery
Jiexin Zhang (2012)
BICD1 expression, as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas
Shang-Pen Huang (2017)
Rhamnose‐coated superparamagnetic iron‐oxide nanoparticles: an evaluation of their in vitro cytotoxicity, genotoxicity and carcinogenicity
Alessandro Paolini (2016)
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
Miranta Antoniou (2016)
Trial Designs for Personalizing Cancer Care: A Systematic Review and Classification
P. Tajik (2013)
Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence
H. Ellis (2015)
Medical management of high-grade astrocytoma: current and emerging therapies.
D. Johnson (2014)